insights_auto
Why is BIIB up 3.33%?
Dive Deeperchevron_right
BIIB:NASDAQ
Biogen Inc
$225.71
arrow_upward
+3.33%(+7.28) 1D
$225.71
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 9, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB...
Open
$220.62
High
$227.20
Low
$219.22
Mkt. cap
33.35B
Avg. vol.
1.01M
Volume
815.01K
P/E ratio
39.97
52-wk high
$230.49
52-wk low
$138.00
EPS
$5.65
Beta
0.09
Shares outstanding
147.75M
No. of employees
8K
Open
$220.62
High
$227.20
Low
$219.22
Mkt. cap
33.35B
Avg. vol.
1.01M
Volume
815.01K
P/E ratio
39.97
52-wk high
$230.49
52-wk low
$138.00
EPS
$5.65
Beta
0.09
Shares outstanding
147.75M
No. of employees
8K
News stories
From web sources and news partners
Traders Union
·
1 day ago
BIIB rallies as mixed signals suggest market indecision
GuruFocus
·
1 day ago
BIIB Maintained by UBS -- Price Target Raised to $270
Stock Traders Daily
·
1 day ago
How (BIIB) Movements Inform Risk Allocation Models
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitebiogen.com